T
1.90
0.01 (0.53%)
| Previous Close | 1.89 |
| Open | 1.90 |
| Volume | 400 |
| Avg. Volume (3M) | 15,803 |
| Market Cap | 1,377,874,304 |
| Price / Earnings (TTM) | 190.00 |
| Price / Sales | 1.26 |
| Price / Book | 1.70 |
| 52 Weeks Range | |
| Earnings Date | 13 Mar 2025 - 17 Mar 2025 |
| Profit Margin | 0.92% |
| Operating Margin (TTM) | 6.39% |
| Diluted EPS (TTM) | 0.010 |
| Quarterly Revenue Growth (YOY) | 58.70% |
| Total Debt/Equity (MRQ) | 53.03% |
| Current Ratio (MRQ) | 1.94 |
| Operating Cash Flow (TTM) | 21.82 M |
| Levered Free Cash Flow (TTM) | -161.79 M |
| Return on Assets (TTM) | 1.19% |
| Return on Equity (TTM) | 1.25% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (HK) | Mixed | Mixed |
| Biotechnology (Global) | Mixed | Mixed | |
| Stock | TOT BIOPHARM-B | - | - |
AIStockmoo Score
0.6
| Analyst Consensus | 0.0 |
| Insider Activity | NA |
| Price Volatility | -2.0 |
| Technical Moving Averages | 2.5 |
| Technical Oscillators | 2.0 |
| Average | 0.63 |
Similar Stocks
| Stock | Market Cap | DY | P/E (TTM) | P/B |
|---|---|---|---|---|
| TOT BIOPHARM-B | 1 B | - | 190.00 | 1.70 |
| GENSCRIPT BIO | 23 B | - | - | 2.42 |
| OCUMENSION-B | 3 B | - | - | 1.17 |
| HBM HOLDINGS-B | 3 B | - | 17.00 | 2.77 |
| AKESO | 55 B | - | - | 9.50 |
| INNOVENT BIO | 53 B | - | - | 4.54 |
|
TOT Biopharm International Co Ltd is a clinical-stage biopharmaceutical company dedicated to developing and commercializing oncology drugs and therapies for patients and their families as well as medical professionals. It has a pipeline of oncology drug candidates, which include monoclonal antibodies (mAbs) and antibody-drug conjugates (ADCs). It generates revenues from Mainland China. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Growth |
| % Held by Insiders | 41.99% |
| % Held by Institutions | 28.40% |
No data within this time range.
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |